Détail du document
Identifiant

doi:10.1186/s12883-021-02187-8...

Auteur
Kjældgaard, Anne-Lene Pilely, Katrine Olsen, Karsten Skovgaard Jessen, Anders Hedegaard Lauritsen, Anne Øberg Pedersen, Stephen Wørlich Svenstrup, Kirsten Karlsborg, Merete Thagesen, Helle Blaabjerg, Morten Theódórsdóttir, Ásta Elmo, Elisabeth Gundtoft Møller, Anette Torvin Bonefeld, Lone Berg, Mia Garred, Peter Møller, Kirsten
Langue
en
Editeur

BioMed Central

Catégorie

Neurology

Année

2021

Date de référencement

08/12/2022

Mots clés
alsfrs-r slope amyotrophic lateral sclerosis median survival time prognostic biomarker disease treatment symptoms test prognostic δfs’ survival
Métrique

Résumé

Introduction Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease with great heterogeneity.

Biological prognostic markers are needed for the patients to plan future supportive treatment, palliative treatment, and end-of-life decisions.

In addition, prognostic markers are greatly needed for the randomization in clinical trials.

Objective This study aimed to test the ALS Functional Rating Scale-Revised (ALSFRS-R) progression rate (ΔFS) as a prognostic marker of survival in a Danish ALS cohort.

Methods The ALSFRS-R score at test date in association with duration of symptoms, from the onset of symptoms until test date, (defined as ΔFS’) was calculated for 90 Danish patients diagnosed with either probable or definite sporadic ALS.

Median survival time was then estimated from the onset of symptoms until primary endpoint (either death or tracheostomy).

ΔFS’ was subjected to survival analysis using Cox proportional hazards modelling, log-rank test, and Kaplan-Meier survival analysis.

Results and conclusions Both ΔFS’ and age was found to be strong predictors of survival of the Danish ALS cohort.

Both variables are easily obtained at the time of diagnosis and could be used by clinicians and ALS patients to plan future supportive and palliative treatment.

Furthermore, ΔFS’, is a simple, prognostic marker that predicts survival in the early phase of disease as well as at later stages of the disease.

Kjældgaard, Anne-Lene,Pilely, Katrine,Olsen, Karsten Skovgaard,Jessen, Anders Hedegaard,Lauritsen, Anne Øberg,Pedersen, Stephen Wørlich,Svenstrup, Kirsten,Karlsborg, Merete,Thagesen, Helle,Blaabjerg, Morten,Theódórsdóttir, Ásta,Elmo, Elisabeth Gundtoft,Møller, Anette Torvin,Bonefeld, Lone,Berg, Mia,Garred, Peter,Møller, Kirsten, 2021, Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study, BioMed Central

Document

Ouvrir

Partager

Source

Articles recommandés par ES/IODE IA

MELAS: Phenotype Classification into Classic-versus-Atypical Presentations
presentations mitochondrial strokelike patients variability phenotype clinical melas
Protocol for the promoting resilience in stress management (PRISM) intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer
cancer quality of life anxiety depression hope coping skills communication intervention randomized ayas outcomes resilience care trial cancer prism-ac advanced